Default company panoramic image

Prescient Surgical

Prescient Surgical has developed the proprietary CleanCision platform for the prevention of surgical wound infections.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Mountain View, CA, USA
  • Currency USD
  • Founded August 2012
  • Employees 3
  • Website

Company Summary

Our mission is to enable safer and more cost effective surgical care by preventing surgical complications, which will benefit patients, providers, hospitals, and payers. The first application of CleanCision technology targets the highest surgical infection rate in the most vulnerable patient segment: obese patients undergoing colorectal surgery. CleanCision provides an active, targeted, wound-based prevention solution to surgeons.


  • Default avatar
    Insoo Suh
    Director and Chief Medical Officer

    Company Founder. General and endocrine surgeon, deep clinical expertise. Education: Biochem (Yale), MD (UCSF)

  • Default avatar
    Jonathan Coe
    President and Chief Operating Officer

    Company Founder. Board Member. 10 years in the medical device industry (J&J, Covidien). Education: Mech Eng (MIT, Georgia Tech)

  • Default avatar
    Joseph Michael Tartaglia
    Director and Senior Adviser

    Board Member. Joseph M. Tartaglia is a senior level executive with extensive medical device experience in both in Fortune 500 and start-up companies. He has over 35 years experience in the medical device industry. He has been in R&D management and general management positions for over 30 of those years.
    Joe has proven leadership abilities in product development, operations, intellectual property management and strategic business planning.

  • Default avatar
    Ferolyn Powell
    Board Chair

    Ferolyn Powell is an executive with over 25 years experiences in the medical device industry. She joined Evalve in 1999 as the President, CEO, and a member of the Board of Directors. She joined Abbott Vascular in November 2009 after Abbott acquired Evalve for $320 million in cash plus $90 million if certain milestones are met. She currently serves as the Divisional Vice President and General Manager of Abbott Vascular Structural Heart.